Updated Review of Nuclear Molecular Imaging of Thyroid Cancers

被引：10

作者：

Fu, Hao ^{[1
,2
]}

Sa, Ri ^{[1
,3
]}

Cheng, Lin ^{[1
]}

Jin, Yuchen ^{[1
]}

Qiu, Xian ^{[1
]}

Liu, Min ^{[1
,4
]}

Chen, Libo ^{[1
]}

机构：

[1] Shanghai Jiao Tong Univ, Dept Nucl Med, Affiliated Peoples Hosp 6, Yishan Rd 600, Shanghai 200233, Peoples R China

[2] Fujian Med Univ, Dept Nucl Med, Teaching Hosp, Xiamen Univ,Affiliated Hosp 1,Xiamen Canc Hosp, Xiamen, Peoples R China

[3] First Hosp Jilin Univ, Dept Nucl Med, Changchun, Peoples R China

[4] Fudan Univ, Zhongshan Hosp, Dept Nucl Med, Shanghai, Peoples R China

来源：

ENDOCRINE PRACTICE | 2021年 / 27卷 / 05期

基金：

中国国家自然科学基金;

关键词：

nuclear molecular imaging; thyroid cancer; nuclear medicine; radiopharmaceuticals; POSITRON-EMISSION-TOMOGRAPHY; PREABLATION 131-I SCANS; WHOLE-BODY SCAN; I-124; PET/CT; F-18-FDG PET; FOLLOW-UP; ASSOCIATION GUIDELINES; INCREASED CALCITONIN; SERUM THYROGLOBULIN; COMPUTED-TOMOGRAPHY;

D O I：

10.1016/j.eprac.2020.10.001

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Objectives: We initiate this comprehensive review to update the advances in this field by objectively elucidating the efficacies of promising radiopharmaceuticals. Methods: We performed a comprehensive PUBMED search using the combined terms of "thyroid cancer" and "radiopharmaceuticals" or "nuclear medicine", yielding 3273 and 11026 articles prior to December 31, 2020, respectively. Results: Based on the mechanism of molecular metabolism, the evaluation of differentiated thyroid cancer and dedifferentiated thyroid cancer is largely centered around radioiodine and fluorine 18 (F-18)-fludeoxyglucose, respectively. Further, F-18-L-dihydroxyphenylalanine and gallium 68 DOTATATE are the preferred tracers for medullary thyroid cancer. In dedifferentiated medullary thyroid cancer and anaplastic thyroid cancer, F-18-fludeoxyglucose is superior. Conclusions: The future lies in advances in molecular biology, novel radiopharmaceuticals and imaging devices, paving ways to the development of personalized medication for thyroid cancer patients. (C) 2020 AACE. Published by Elsevier Inc. All rights reserved.

引用

页码：494 / 502

页数：9

共 99 条

[71] 18F-FDG-Avid Thyroid Incidentalomas: The Importance of Contextual Interpretation [J].

Pattison, David A. ;

Bozin, Michael ;

Gorelik, Alexandra ;

Hofman, Michael S. ;

Hicks, Rodney J. ;

Skandarajah, Anita .

JOURNAL OF NUCLEAR MEDICINE, 2018, 59 (05) :749-755

[72] 18F-fluorodeoxyglucose positron emission tomography and computed tomography in anaplastic thyroid cancer [J].

Poisson, Thomas ;

Deandreis, Desiree ;

Leboulleux, Sophie ;

Bidault, Francois ;

Bonniaud, Guillaume ;

Baillot, Sylvain ;

Auperin, Anne ;

Al Ghuzlan, Abir ;

Travagli, Jean-Paul ;

Lumbroso, Jean ;

Baudin, Eric ;

Schlumberger, Martin .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2010, 37 (12) :2277-2285

[73] Diagnostic Performance of 18F-FDG PET/CT in Papillary Thyroid Carcinoma with Negative 131I-WBS at first Postablation, Negative Tg and Progressively Increased TgAb Level [J].

Qiu, Zhong-Ling ;

Wei, Wei-Jun ;

Shen, Chen-Tian ;

Song, Hong-Jun ;

Zhang, Xin-Yun ;

Sun, Zhen-Kui ;

Luo, Quan-Yong .

SCIENTIFIC REPORTS, 2017, 7

[74] Diagnostic utility of PET/CT with 18F-DOPA and 18F-FDG in persistent or recurrent medullary thyroid carcinoma: the importance of calcitonin and carcinoembryonic antigen cutoff [J].

Reyes Romero-Lluch, Ana ;

Ignacio Cuenca-Cuenca, Juan ;

Guerrero-Vazquez, Raquel ;

Jesus Martinez-Ortega, Antonio ;

Luis Tirado-Hospital, Juan ;

Borrego-Dorado, Isabel ;

Navarro-Gonzalez, Elena .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 (12) :2004-2013

[75] The value of positron emission tomography (PET) in the management of patients with thyroid cancer [J].

Robbins, Richard J. ;

Larson, Steven M. .

BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 2008, 22 (06) :1047-1059

[76] 177Lu-DOTATATE Therapy in Radioiodine-refractory Differentiated Thyroid Cancer: A Single Center Experience [J].

Roll, Wolfgang ;

Riemann, Burkhard ;

Schaefers, Michael ;

Stegger, Lars ;

Vrachimis, Alexis .

CLINICAL NUCLEAR MEDICINE, 2018, 43 (10) :E346-E351

[77] Redifferentiation of Iodine-Refractory BRAF V600E-Mutant Metastatic Papillary Thyroid Cancer with Dabrafenib-Response [J].

Rothenberg, S. Michael ;

Daniels, Gilbert H. ;

Wirth, Lori J. .

CLINICAL CANCER RESEARCH, 2015, 21 (24) :5640-5641

[78] 18F-FDG PET predicts survival after pretargeted radioimmunotherapy in patients with progressive metastatic medullary thyroid carcinoma [J].

Salaun, Pierre-Yves ;

Campion, Loic ;

Ansquer, Catherine ;

Frampas, Eric ;

Mathieu, Cedric ;

Robin, Philippe ;

Bournaud, Claire ;

Vuillez, Jean-Philippe ;

Taieb, David ;

Rousseau, Caroline ;

Drui, Delphine ;

Mirallie, Eric ;

Borson-Chazot, Francoise ;

Goldenberg, David M. ;

Chatal, Jean-Francois ;

Barbet, Jacques ;

Kraeber-Bodere, Francoise .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 (08) :1501-1510

[79] Initial Clinical Investigation of [18F]Tetrafluoroborate PET/CT in Comparison to [124I]Iodine PET/CT for Imaging Thyroid Cancer [J].

Samnick, Samuel ;

Al-Momani, Ehab ;

Schmid, Jan-Stefan ;

Mottok, Anja ;

Buck, Andreas K. ;

Lapa, Constantin .

CLINICAL NUCLEAR MEDICINE, 2018, 43 (03) :162-167

[80] Utility of I-124 PET/CT in identifying radioiodine avid lesions in differentiated thyroid cancer: a systematic review and meta-analysis [J].

Santhanam, Prasanna ;

Taieb, David ;

Solnes, Lilja ;

Marashdeh, Wael ;

Ladenson, Paul W. .

CLINICAL ENDOCRINOLOGY, 2017, 86 (05) :645-651

← 1 2 3 4 5 6 7 8 9 10 →